Truncated Recombinant ADAMTS13 Microparticle Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of human recombinant ADAMTS13 have a limited half-life, requiring frequent intravenous administration for long-term supplementation, which is inconvenient and inefficient for treating thrombotic diseases involving von Willebrand factor.
Innovation Solution
Development of a truncated modified recombinant ADAMTS13 (mrADAMTS13) encapsulated in synthetic microparticles for extended release, allowing administration via various routes and providing stable plasmatic concentrations for an extended period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current formulation of human recombinant ADAMTS13 is administered intravenously, then therapeutic effect is achieved, but administration frequency must be repeated frequently due to limited half-life
Solution Approach 1:
The patent encapsulates the ADAMTS13 protein within synthetic microparticles, creating a nested structure where the therapeutic agent is contained within a protective carrier system. This nesting approach extends the duration of action by controlling the release kinetics of the protein from the microparticle matrix, thereby reducing administration frequency while maintaining therapeutic efficacy.
Solution Approach 2:
The patent modifies the ADAMTS13 protein through truncation and engineering before encapsulation, creating a stabilized form with enhanced properties. This preliminary modification of the protein structure prepares it for extended release and improves its stability within the microparticle formulation, addressing the limited half-life issue before administration.
2Reliability
If intravenous administration is used for current ADAMTS13 formulation, then therapeutic delivery is achieved, but patient convenience and quality of life are reduced due to frequent dosing
Solution Approach 1:
By nesting the ADAMTS13 protein within synthetic microparticles designed for extended release, the patent enables less frequent administration intervals. This nested delivery system maintains reliable therapeutic delivery while significantly improving patient convenience by reducing the burden of frequent intravenous access and dosing.
Solution Approach 2:
The patent changes the release rate parameter of the therapeutic agent through encapsulation in microparticles with controlled porosity and degradation characteristics. This parameter change extends the effective duration of action, allowing for less frequent dosing schedules that improve patient convenience while maintaining reliable therapeutic delivery.
3Stability of the object's composition
If truncated modified recombinant ADAMTS13 is encapsulated in synthetic microparticles, then extended release and stable plasmatic concentrations are achieved, but formulation complexity increases
Solution Approach 1:
The patent uses nested microparticle encapsulation to achieve stable plasmatic concentrations through controlled release. While this increases formulation complexity, the synthetic microparticles provide a protective matrix that stabilizes the truncated ADAMTS13 protein, preventing degradation and ensuring consistent therapeutic levels over extended periods.
Solution Approach 2:
The patent employs composite material structures combining synthetic microparticle matrices with the truncated ADAMTS13 protein. This composite approach enables controlled release kinetics and stable plasmatic concentrations, with the microparticle material providing structural integrity and controlled degradation properties that simplify the overall formulation strategy despite increased complexity.
Data Source
AI summary
Provided herein are polypeptides that are truncated modified recombinant forms of ADAMTS13, nucleic acid molecules encoding the polypeptides, drug delivery compositions and pharmaceutical compositions comprising the polypeptides, and methods of using the polypeptides and compositions (e.g., in the treatment of thrombotic thrombocytopenic purpura (TTP)).